Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial
Open Access
- 16 August 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 220 (11) , 1816-1825
Abstract
Background: Respiratory syncytial virus (RSV) is a common cause of respiratory tract illness and hospitalization in neonates and infants. RSV vaccination during pregnancy may protect offspring in their first months of life. Methods: This randomized, observer-blind, multicenter, phase 2 study evaluated the immunogenicity and safety of an RSV candidate vaccine in healthy nonpregnant women aged 18–45 years. Four hundred participants were randomized (1:1:1:1) to receive a single intramuscular dose of vaccine containing 30 µg, 60 µg, or 120 µg of RSV fusion protein engineered to preferentially maintain a prefusion conformation (RSV-PreF vaccine) or placebo. Results: Thirty days postvaccination, RSV-A neutralizing antibody geometric mean titers (GMTs) increased 3.75-, 4.42- and 4.36-fold; RSV-B neutralizing antibody GMTs 2.36-, 2.54- and 2.76-fold; and palivizumab competing antibody (PCA) concentrations 11.69-, 14.38- and 14.24-fold compared with baseline levels in the 30 µg, 60 µg, and 120 µg RSV-PreF groups, respectively. Antibody titers and PCA concentrations at day 30 were significantly higher with the 120 µg compared to the 30 µg RSV-PreF vaccine. All RSV-PreF vaccine formulations and the placebo had similar reactogenicity profiles. No serious adverse events were considered to be related to the RSV-PreF vaccine. Conclusions: The 3 formulations of the investigational RSV-PreF vaccine were well-tolerated and induced RSV-A and RSV-B neutralizing antibodies and PCAs in healthy, nonpregnant women. Clinical Trials Registration: NCT02956837.Keywords
Funding Information
- GlaxoSmithKline Biologicals SA
This publication has 33 references indexed in Scilit:
- Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical interventionProceedings of the National Academy of Sciences, 2012
- Role of Neutralizing Antibodies in Adults With Community-Acquired Pneumonia by Respiratory Syncytial VirusClinical Infectious Diseases, 2012
- Progress in Respiratory Virus Vaccine DevelopmentSeminars in Respiratory and Critical Care Medicine, 2011
- Cost Effectiveness of Respiratory Syncytial Virus ProphylaxisPharmacoEconomics, 2010
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009
- Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodiesVaccine, 2003
- Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of MozambiqueJournal of Medical Virology, 2002
- Respiratory Syncytial Virus and Parainfluenza VirusNew England Journal of Medicine, 2001
- Risk of Primary Infection and Reinfection With Respiratory Syncytial VirusArchives of Pediatrics & Adolescent Medicine, 1986
- Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody levelThe Journal of Pediatrics, 1981